Aeterna Zentaris

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company, which engages in the development of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

COSCIENS Biopharma Inc. Is a specialty biopharmaceutical company, which engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Canada.

– Live video webcast presentation on Wednesday, January 26 th at 9:00 AM ET

Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference

CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna Zentaris, will present at the virtual H.C. Wainwright Bio C onnect Conference taking place January 10-13, 2022.

Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference

– Well-established finance professional with over 20 years of experience gained in pharmaceutical, biopharma and professional services sectors

Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer

Zomedica

Progenity

A few hot penny stocks are seeing major movement on Friday as shares ride higher and we've got all the details traders need. The post 3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today appeared first on InvestorPlace.

3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today

CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna, will present at the virtual H.C. Wainwright 23 rd Annual Global Investment Conference taking place September 13-15, 2021.

Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

CHARLESTON, S.C., July 29, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that on July 28, 2021, the Company received notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon a closing bid price of less than $1.00 per share for the Company's common stock for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5550(a)(2) (the “Rule”).

Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing

Amarin Corporation Plc

DURECT

Globus Maritime

CarLotz

MediWound

Intec Parent

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 7 To Watch This Week

– Dr. Levy is a well-established n euroimmunologist with extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders

Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs

CHARLESTON, S.C., June 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced the U.S. District Court for the District of New Jersey has given final approval of the settlement from the previously disclosed class-action lawsuit against the Company. The settlement payment will be funded entirely by the Company's insurers. Pending no action taken during the 30-day appeal period, this matter will be considered fully and finally settled.

Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit

- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of m acimorelin for the treatment of ALS

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's Disease)

Aeterna Zentaris Inc (NASDAQ: AEZS) has commenced its pivotal Phase 3 DETECT trial evaluating macimorelin as a diagnosis of childhood-onset growth hormone deficiency (CGHD). The investigational new drug application multicenter, open-label trial will investigate the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as a growth hormone stimulation test (GHST) in pediatric patients with suspected GHD.

Aeterna Zentaris Starts Research Study On How Well Macimorelin Works For Growth Hormone Deficiency Diagnosis

– Safety and efficacy study for macimorelin initiated as agreed with U . S . FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP")

Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

– Live video webcast with CEO, Dr. Klaus Paulini, on Monday, May 17, 2021 at 8:45 AM ET

Aeterna Zentaris to Present at the Q2 Virtual Investor Summit

In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical study.

Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism

CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced the results from its Annual General Meeting (“AGM”) held today, May 5, 2021.

Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders

– Q1 2021 marked by solid operational execution with expansion and diversification of pipeline , intellectual property and portfolio of assets

Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates

– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncology

Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer

CHARLESTON, S.C., April 28, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced its Annual General Meeting ("AGM") will be held on May 5, 2021 at 10:00 a.m. ET. Due to the impact of the COVID-19 pandemic, the meeting will be held virtually.

Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders

Micronet Enertec Technologies

Zosano Pharma

As April comes to an end, are these 3 penny stocks worth watching? The post 3 Penny Stocks to Watch During the Last Week of April appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Watch During the Last Week of April

– Company executing on growth strategy to build-out pipeline of development assets

Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results

CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that on March 22, 2021, it received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum $1.00 bid price per share requirement under Nasdaq's Listing Rule 5550(a)(2).

Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement

Investors in AEZS stock have continued to pile into this trade today, with the stock up more than 40% on news around its Covid-19 vaccine. The post AEZS Stock: Why Aeterna Zentaris Shares Are Shooting Higher Today appeared first on InvestorPlace.

AEZS Stock: Why Aeterna Zentaris Shares Are Shooting Higher Today

Aeterna Zentaris Inc (NASDAQ: AEZS) has exercised its option announced on February 2, and entered into an exclusive worldwide sub-licensable patent and know-how license agreement for a potential COVID-19 vaccine. The vaccine is currently in preclinical development and was invented at the Julius-Maximilians-University in Wuerzburg.

Aeterna Zentaris Shares Are Trading Higher On Announcing Licensing Pact For Development Of Prophylactic COVID-19 Vaccine Candidate

The stock price of AEterna Zentaris Inc. (NASDAQ: AEZS) increased by over 10% pre-market. This is why it happened.

AEZS Stock Price Increases Over 10% Pre-Market: Why It Happened

- Company secures next step to continue to build-out pipeline of assets

Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19

News for Aeterna Zentaris Stock (AEZS)